Lack of standard of care treatments.
While the CDC estimates that greater than 2% of all children have autism spectrum disorder, and that it’s prevalence is growing at 7% a year, no current standard of care treatments exist.
ABT: Revolutionizing Therapeutic Interventions
An Activated Bacterial Therapeutic platform which allows for delivery of microbiome-targeting bacteria, allowing for direct modulation of autism and other nervous system disease pathways.
USD 40B market
Scioto Biosciences is planning to initially target adult autism, presenting a ~$40B addressable market opportunity.
“We think SB-121 can potentially make a big impact in the lives of patients diagnosed with AD”
Jisoo Pae, MD (Founder/CEO of Genome and Company)